We are analyzing https://link.springer.com/article/10.1007/s00125-012-2658-2.

Title:
Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial | Diabetologia
Description:
Aims/hypothesis Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans. Methods A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27–43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or placebo, which were randomly allocated from a sequentially numbered list. The primary outcomes were adipocyte size and capillary density measured by immunohistochemistry, and angiogenic potential assessed by capillary sprout formation in Matrigel. Secondary outcomes were serum adiponectin, glycaemic, lipid and liver function variables. Results A total of 35 individuals fulfilling the inclusion criteria were randomised, and complete before-vs-after analyses were achieved in 30 participants (13 and 17, placebo and rosiglitazone, respectively). Significant differences, assessed by paired two-tailed Student t tests, were seen in response to rosiglitazone for adipocyte size (3,458 ± 202 vs 2,693 ± 223 μm2, p = 0.0049), capillary density (5.6 ± 0.5 vs 7.5 ± 0.5 lumens/field, p = 0.0098), serum adiponectin (14.3 ± 1.5 vs 28.6 ± 3.0 ng/ml, p < 0.0001) and alkaline phosphatase (1.04 ± 0.07 vs 0.87 ± 0.05 μkat/l, p = 0.001). A difference in angiogenic potential before and after treatment between the placebo and rosiglitazone groups was also seen (−23.88 ± 14 vs 13.42 ± 13, p = 0.029, two-tailed Mann–Whitney test). Conclusions/interpretation Significant effects on adipose tissue vascular architecture occur after a short period of treatment with rosiglitazone in individuals with normal glucose tolerance. Improved adipose tissue vascularisation may, in part, mediate the therapeutic actions of this class of drugs. Trial registration ClinicalTrials.gov NCT01150981 Funding The study was funded by National Institutes of Health grant DK089101 to S. Corvera, and by pilot funding from the University of Massachusetts (UMASS) Center for Clinical Translational Sciences (M. Thompson, S. Malkani and S. Corvera). Morphology core services were supported by UMASS Diabetes Endocrine Research Center (DERC) grant DK32520.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

tissue, adipose, capillary, rosiglitazone, growth, insulin, article, density, study, adipocytes, fig, placebo, size, angiogenesis, individuals, resistance, adipocyte, glucose, treatment, test, google, scholar, serum, adiponectin, significant, twotailed, rate, pubmed, cas, data, manuscript, corvera, usa, paired, obese, angiogenic, tzds, number, analysis, trial, measured, participants, student, difference, effects, endothelial, small, vivo, human, privacy,

Topics {✒️}

investigator-blinded placebo-controlled trial adipose-tissue-specific angiogenesis pre-formed capillary beds contralateral peri-umbilical region growth-factor-depleted matrigel tailed mann–whitney test adipose tissue angiogenesis endothelial cell function subcutaneous adipose tissue fat mass loss human adipose tissue adipose tissue architecture peri-umbilical region research triangle park privacy choices/manage cookies postmenopausal diabetic women massachusetts medical school randomised controlled trial improving tissue perfusion precursor cells embedded mammary tumor growth article gealekman lipid metabolism underlie insulin resistance vivo angiogenesis assay growth rate decreases main content log sequentially numbered list health grant dk089101 clinical translational sciences nerl diagnostics llc electronic supplementary material adverse event assessments bd discovery labware obese human subjects inflammatory gene expression electronic supplementary materials capillary growth rate conditions privacy policy scale bar 100 μm scale bar 250 μm angiogenic growth rate initial capillary density increasing capillary density linear regression analysis depot-specific differences provided critical revisions represent angiogenic growth stimulate adipocyte differentiation obese zucker rats

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial
         description:Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans. A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27–43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or placebo, which were randomly allocated from a sequentially numbered list. The primary outcomes were adipocyte size and capillary density measured by immunohistochemistry, and angiogenic potential assessed by capillary sprout formation in Matrigel. Secondary outcomes were serum adiponectin, glycaemic, lipid and liver function variables. A total of 35 individuals fulfilling the inclusion criteria were randomised, and complete before-vs-after analyses were achieved in 30 participants (13 and 17, placebo and rosiglitazone, respectively). Significant differences, assessed by paired two-tailed Student t tests, were seen in response to rosiglitazone for adipocyte size (3,458 ± 202 vs 2,693 ± 223 μm2, p = 0.0049), capillary density (5.6 ± 0.5 vs 7.5 ± 0.5 lumens/field, p = 0.0098), serum adiponectin (14.3 ± 1.5 vs 28.6 ± 3.0 ng/ml, p < 0.0001) and alkaline phosphatase (1.04 ± 0.07 vs 0.87 ± 0.05 μkat/l, p = 0.001). A difference in angiogenic potential before and after treatment between the placebo and rosiglitazone groups was also seen (−23.88 ± 14 vs 13.42 ± 13, p = 0.029, two-tailed Mann–Whitney test). Significant effects on adipose tissue vascular architecture occur after a short period of treatment with rosiglitazone in individuals with normal glucose tolerance. Improved adipose tissue vascularisation may, in part, mediate the therapeutic actions of this class of drugs. ClinicalTrials.gov NCT01150981 The study was funded by National Institutes of Health grant DK089101 to S. Corvera, and by pilot funding from the University of Massachusetts (UMASS) Center for Clinical Translational Sciences (M. Thompson, S. Malkani and S. Corvera). Morphology core services were supported by UMASS Diabetes Endocrine Research Center (DERC) grant DK32520.
         datePublished:2012-07-31T00:00:00Z
         dateModified:2012-07-31T00:00:00Z
         pageStart:2794
         pageEnd:2799
         sameAs:https://doi.org/10.1007/s00125-012-2658-2
         keywords:
            Adipose tissue expandability
            Angiogenesis
            Endothelial cells
            Insulin resistance
            Thiazolidinediones
            Vascularisation
            Internal Medicine
            Metabolic Diseases
            Human Physiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2658-2/MediaObjects/125_2012_2658_Fig1_HTML.gif
         isPartOf:
            name:Diabetologia
            issn:
               1432-0428
               0012-186X
            volumeNumber:55
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:O. Gealekman
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Guseva
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Gurav
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Gusev
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Hartigan
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Thompson
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Malkani
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Corvera
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial
      description:Recent reports of decreased capillary density in the adipose tissue of obese individuals suggest that an imbalance of angiogenesis and adipogenesis may, in part, underlie insulin resistance. This study aimed to determine whether the insulin-sensitising peroxisome proliferator-activated receptor γ (PPARγ) activator rosiglitazone affects adipose tissue vascularisation in normal humans. A randomised, parallel-group, investigator-blinded placebo-controlled trial was conducted with normoglycaemic volunteers with BMI 27–43, recruited from the community at the University of Massachusetts Medical School, Worcester, MA, USA. Peri-umbilical adipose tissue biopsies were obtained before and after treatment for 6 weeks with rosiglitazone (8 mg once daily) or placebo, which were randomly allocated from a sequentially numbered list. The primary outcomes were adipocyte size and capillary density measured by immunohistochemistry, and angiogenic potential assessed by capillary sprout formation in Matrigel. Secondary outcomes were serum adiponectin, glycaemic, lipid and liver function variables. A total of 35 individuals fulfilling the inclusion criteria were randomised, and complete before-vs-after analyses were achieved in 30 participants (13 and 17, placebo and rosiglitazone, respectively). Significant differences, assessed by paired two-tailed Student t tests, were seen in response to rosiglitazone for adipocyte size (3,458 ± 202 vs 2,693 ± 223 μm2, p = 0.0049), capillary density (5.6 ± 0.5 vs 7.5 ± 0.5 lumens/field, p = 0.0098), serum adiponectin (14.3 ± 1.5 vs 28.6 ± 3.0 ng/ml, p < 0.0001) and alkaline phosphatase (1.04 ± 0.07 vs 0.87 ± 0.05 μkat/l, p = 0.001). A difference in angiogenic potential before and after treatment between the placebo and rosiglitazone groups was also seen (−23.88 ± 14 vs 13.42 ± 13, p = 0.029, two-tailed Mann–Whitney test). Significant effects on adipose tissue vascular architecture occur after a short period of treatment with rosiglitazone in individuals with normal glucose tolerance. Improved adipose tissue vascularisation may, in part, mediate the therapeutic actions of this class of drugs. ClinicalTrials.gov NCT01150981 The study was funded by National Institutes of Health grant DK089101 to S. Corvera, and by pilot funding from the University of Massachusetts (UMASS) Center for Clinical Translational Sciences (M. Thompson, S. Malkani and S. Corvera). Morphology core services were supported by UMASS Diabetes Endocrine Research Center (DERC) grant DK32520.
      datePublished:2012-07-31T00:00:00Z
      dateModified:2012-07-31T00:00:00Z
      pageStart:2794
      pageEnd:2799
      sameAs:https://doi.org/10.1007/s00125-012-2658-2
      keywords:
         Adipose tissue expandability
         Angiogenesis
         Endothelial cells
         Insulin resistance
         Thiazolidinediones
         Vascularisation
         Internal Medicine
         Metabolic Diseases
         Human Physiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00125-012-2658-2/MediaObjects/125_2012_2658_Fig1_HTML.gif
      isPartOf:
         name:Diabetologia
         issn:
            1432-0428
            0012-186X
         volumeNumber:55
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:O. Gealekman
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Guseva
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Gurav
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Gusev
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Hartigan
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Thompson
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Malkani
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Corvera
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Diabetologia
      issn:
         1432-0428
         0012-186X
      volumeNumber:55
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Massachusetts Medical School
      address:
         name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:O. Gealekman
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:N. Guseva
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:K. Gurav
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:A. Gusev
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:C. Hartigan
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:M. Thompson
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:S. Malkani
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:S. Corvera
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Department of Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, USA

External Links {🔗}(71)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.07s.

LINK . SPRINGER . COM {}